Intestinal nutrient absorption pathway alteration

Intestinal nutrient absorption pathway alteration refers to the therapeutic or pathological modification of the mechanisms responsible for the uptake of nutrients across the gastrointestinal tract. This is not a single molecular target but a physiological process involving a suite of enzymes and transporters, such as pancreatic lipase, alpha-glucosidase, and the NPC1L1 cholesterol transporter (PubMed, PMID: 15131263). Pharmacological intervention in these pathways is primarily used to manage metabolic conditions like obesity and type 2 diabetes by limiting the absorption of fats and sugars. For instance, lipase inhibitors like Orlistat prevent the breakdown of dietary triglycerides into absorbable free fatty acids (StatPearls, PMID: 28722907). Similarly, alpha-glucosidase inhibitors like Acarbose delay carbohydrate digestion to flatten postprandial glucose spikes (PubMed, PMID: 10511231). Transporters like SGLT1 are also targets for reducing glucose uptake in the small intestine (UniProt, P13866). However, excessive or unintended alteration of these pathways can lead to malabsorption syndromes, characterized by nutrient deficiencies and significant gastrointestinal side effects.

Other names

Intestinal malabsorptionNutrient uptake modulationEnteric nutrient transport alterationGastrointestinal absorption inhibition

Inhibition of digestive enzymes (e.g., gastric and pancreatic lipases, alpha-glucosidases) or blockade of specific apical membrane transporters (e.g., NPC1L1, SGLT1) to reduce the systemic absorption of fats, carbohydrates, or cholesterol (StatPearls, PMID: 28722907; PubMed, PMID: 15131263).